Hormone-replacement therapy, dementia and stroke

Women's Health

Volumn 3, Issue 6, 2007, Pages 699-710

  Billeci, A M R ^a   Caso, V ^a   Paciaroni, M ^a   Palmerini, F ^a   Agnelli, G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Dementia; Estrogen; Hormone replacement therapy; Menopause; Stroke; Women

Indexed keywords

ACETYLSALICYLIC ACID; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SEX HORMONE;

ALZHEIMER DISEASE; ARTERY EMBOLISM; ARTERY THROMBOSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; EXPERIMENTAL STUDY; FRAGILITY FRACTURE; HIGH RISK PATIENT; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MENTAL PERFORMANCE; MONOTHERAPY; NONHUMAN; OBSERVATIONAL STUDY; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYMPTOM; VENOUS THROMBOEMBOLISM;

EID: 37249001769     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.6.699     Document Type: Review

References (116)

1. Payami H, Montee K, Grimslid H, Shattuc S, Kaye J: Increased risk of familial late-onset Alzheimer's disease in women. Neurology 46, 126-129 (1996).
2. Paganini-Hill A, Henderson VW: Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140, 256-261 (1994).
3. Zekry D, Duyckaerts; C, Moultas R, Belmin J, Herrmann F, Hauw JJ: Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol. (Berl.) 103, 481-487 (2002).
4. Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr. Scand. 76, 465-479 (1987).
5. Gao S, Hendrie HC, Hall KS, Hui S: The relationships between age, sex, and incidence of dementia and Alzheimer's disease: a meta-analysis. Arch. Gen. Psychiatry 55, 809-815 (1998).
6. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Schrerer J, Gulanski B: The Alzheimer's disease assessment scale patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease traits. Neurology 48, 1511-1517 (1997).
7. Launer L, Andersen K, Dewy ME et al.: Rates and risk factors for dementia and Alzheimer's disease. Neurology 1, 78-84 (1990).
8. Rocca WA, Bonaiuto S, Lippi A et al.: Prevalence of clinically diagnosed Alzheimer's and other dementing disorders. Neurology 40, 626-631 (1990).
9. Hagnell O, Öjedsjö L, Rorsman B: Incidence of dementia in the Lundby study. Neuroepidemiology 11 (Suppi. 1), 61-66 (1992).
10. Kokmen E, Beard CM, O'Brien PC, Kurkand LT: Epidemiology of dementia in Rochester, Minnesota. Mayo Clin. Proc. 71, 275-282 (1996).
11. Maas D, Jochen A, Lalande B: Age related changes in male gonadal function. Implications for therapy. Drugs Ageing 11, 45-60 (1997).
12. Henderson VW, Paganini-Hill A, Miller BL et al.: Estrogen for Alzheimer's disease in women. Neurology 54, 295-301 (2000).
13. Wang PN, Liao SQ, Liu RS et al.: Effects of estrogen on cognition, mood, and cerebral blood flow in AD. Neurology 54, 2061-2066 (2000).
14. Mulnard RA, Cotman CW, Kawas C et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 28, 1007-1015 (2000).
15. Hurn PD, Brass LM: Estrogen and stroke: a balanced analysis. Stroke 34, 338-341 (2003).
16. Marini C, de Santis F, Sacco S et al.: Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36(6), 1115-1119 (2005).
17. James A, Bushnell CD, Jamison M, Myers E: Incidence and risk factors for stroke in pregnancy and the purperium. Obstet. Gynecol. 106, 509-516 (2005).
18. Gillum LA, Mamidipudi SK, Johnston SC: Ischemic stroke risk with oral contraceptive. A meta-analysis. JAMA 284, 72-78 (2000).
19. Chan WS, Ray J, Wai EK et al.: Risk of stroke in women exposed to low-dose oral contraceptives. A critical evaluation of the evidence. Arch. Intern. Med. 164, 741-747 (2004).
20. Bonita R: Epidemiology of stroke. Lancet 339, 342-344 (1992).
21. Wolf PA, D'Agostino RB, Balanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 22, 312-318 (1991).
22. Glader EL, Stegmayr B, Norrwing B et al.: Sex differences in management and outcome after stroke. A Swedish national perspective. Stroke 34, 1970-1975 (2003).
23. di Carlo A, Lamassa M, Baldreschi M et al.: Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe. Data from a Multicenter Multinational Hospital-Based Registry. Stroke 34, 1114-1119 (2003).
24. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A: A population-based study of dementia in 85-years old. N. Engl. J. Med. 328, 153-158 (1993).
25. Shughrue PJ, Scrimo PJ, Merchenthaler I: Estrogen binding and estrogen receptor characterization (ERα and ERβ) in the cholinergic neurons of the rat basal forebrain. Neuroscience 96, 41-49 (2000).
26. Alkayed N, Murphy S, Traystman R, Hurn P, Miller V: Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 31, 161-168 (2000).
27. Goodman Y, Bruce AJ, Cheng B, Mattson MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J. Neurochem. 66, 1836-1844 (1996).
28. Brinton RD, Tran J, Proffitt P, Montoya M: 17β-estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem. Res. 22, 1339-1351 (1997).
29. Foy MR, Henderson VW, Berger TW, Thompson RF: Estrogen and neural plasticity. Curr. Direct. Psychol. Sci. 9, 148-152 (2000).
30. Ohkura T, Teshima Y, Isse K et al.: Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause 2, 13-18 (1995).
31. Bishop J, Simpkins JW: Estradiol enhances brain glucose update in ovariectomized rats. Brain Res. Bull. 36, 315-320 (1995).
32. Petanceska SS, Nagy G, Frail D, Gandy S: Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amytoid-β peptides in brain. Neurology 54, 2212-2217 (2000).
33. Janowsky DS, Daris JM: Progesterone-estrogen effects on the uptake and release of norepinephrine by synaptosomes. Life Sci. 9, 525-531 (1970).
34. Luine VN, McEwen BS: Effect of estradiol on turnover of type A monoamine oxidase in brain. J. Neurochem. 28, 1221-1227 (1977).
35. Luine VN: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection area of female rats. Expl. Neurol. 89, 484-490 (1985).
36. Gibbs RB: Estrogen and nerve growth factor-related systems in brain. Ann. NY Acad. Sci. 14, 165-199 (1994).
37. Woolley C, McEwen BS: Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during oestrus cycles in the rat. J. Comp. Neurol. 336, 293-306 (1993).
38. McEwen BS, Alves SE, Bulloch K, Weiland NG: Ovarian steroids and the brain implications for cognition and ageing. Neurology, 48, S14-S18 (1997).
39. Sarrel PM: Effects of ovarian steroids on the cardiovascular system. In: The Circulation of the Female from the Cradle to the Grave. Ginsberg J (Ed.). Parthenon, Carnford, UK (1989).
40. Sarrel PM: Ovarian hormones and the circulation. Maturitas 590, 287-298 (1990).
41. O'Rourke ST Vanhoutte PM, Miller VM: Vascular pharmacology. In: Vascular Medicine: A Companion to Braunwalds Heart Disease. Creager MA, Dzau V, Loscalso J (Eds). Elsevier, PA, USA 71-100 (2006).
42. Ridker PM, Cook NR, Lee I-M et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293-1304 (2005).
43. Lieberman EH, Gerhard MD, Uehata A et al.: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 121, 936-941 (1994).
44. Rossouw JE, Anderson GL, Prentice RL et al.: Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
45. Rapp SR, Espeland MA, Shumaker SA et al.: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Womens Health Initiative Memory Study: a randomized control trial. JAMA 289, 2663-2672 (2003).
46. Shumaker SA, Legault C, Rapp SR et al.; for the WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized clinical trial. JAMA 289, 2651-2662 (2003).
47. Anderson GL, Limacher M, Assaf AR et al.: Effect of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Steering Committee. JAMA 291, 1701-1712 (2004).
48. Holst J, Cajander S, Carlstrom K et al.: A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Br. J. Obstet. Gynaecol. 90, 355-360 (1983).
49. de Lignieres B: The case for a non-plasma lipoprotein etiology of reduced vascular risk in estrogen replacement therapy. Curr. Opin. Obstet. Gynecol. 5, 389-395 (1993).
50. de Lignieres B, Mauvais-Jarvis P: Postmenopausal hormonal therapy. In: Ovarian Endocrinology. Scholler R (Ed.). SEPE, Paris, France 578-592 (1976).
51. de Lignieres B, Basdevant A, Thomas G et al.: Biological effects of estradiol-17β in postmenopausal women: oral versus transdermal administration. J. Clin. Endocrinol. Metab. 62, 536-541 (1986).
52. Moorjani S, Dupont A, Labrie F et al.: Changes in plasma lipoprotein and apolipoprotein composition in relation to oral vesrsus transdermal administration of estrogens. J. Clin. Endocrinol. Metab. 73, 373-379 (1991).
53. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G et al.: Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 17, 3071-3078 (1997).
54. Godsland IF: Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil. Steril. 75, 898-915 (2001).
55. Wakatsuki A, Okatani Y, Ikenoue N et al.: Different effects of oral conjugated equine strogen and transdermal estrogen replacement on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106, 1771-1776 (2002).
56. Venkov CD, Rankin AB, Douglas E et al.: Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 94, 727-733 (1996).
57. Kim-Schulze S, McGowan K, Hubchak SC et al.: Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 94, 1402-1407 (1996).
58. Alvarez RJ, Gips SJ, Moldovan N et al.: 17β-estradiol inhibits apoptosis of endothelial cells. Biochem. Biophys. Res. Commun. 237, 372-381 (1997).
59. Iwakura A, Luedemann C, Shasrty S et al.: Estrogenmediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108, 3115-3121 (2003).
60. SimonciniT, Genazzani AR: Direct vascular effects of estrogens and selective estrogen receptor modulators. Curr. Opin. Obstet. Gynecol. 12, 181-187 (2000).
61. Simoncini T, Hafezi-Moghadam A, Brazil D, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538-541 (2000).
62. Simoncini T, Genazzani AR: Non-genomic actions of sex steroid hormones. Eur. J. Endocrinol. 148,281-292 (2003).
63. Vazquez F, Rodriguez-Manzanesque JC, Lydon JP et al.: Progesterone regulates proliferation of endothelial cells. J. Biol. Chem. 274, 2185-2192 (1999).
64. Adams MR, Register TC, Golden DL,Wagner JD, Williams JK: Medroxyprogesterone acetate antagonizes inhibitory effects or conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vast. Biol. 17, 217-221 (1997).
65. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K: Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3, 324-327 (1997).
66. Cheng W, Lau OD, Abumrad NA: Two antiatherogenic effects of progesterone on human macrophages; inhibition of cholesteryl ester synthesis and block of its enhancement by glucocorticoids. J. Clin. Endocrinol. Metab. 84, 265-271 (1999).
67. Otsuki M, Saito H, Xu X et al.: Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler. Thromb. Vast. Biol. 21, 243-248 (2001).
68. Xing D, Miller A, Novak L et al.: Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 109, 234-241 (2004).
69. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR: In vitro effects of progesterone and progestins on vascular cells. Steroids 68, 831-836 (2003).
70. Grady D, Herrington D, Bittner V et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy (HERS II). JAMA 288, 49-57 (2002).
71. Hoibraaten E, Qvigstad E, Arnesen H et al.: Increased risk of recurrent venous thromboembolism during hormone replacement therapy results of the randomized, double-blind, placebo controlled estrogen in venous thromboembolism trial. Thromb. Haemost. 84, 961-967 (2000).
72. Barrett-Connor E: An epidemiologist looks at hormones and heart disease in women. J. Clin. Endocrinol. Metab. 88, 4031-4042 (2003).
73. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP: Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thrumb. Vasc. Biol. 19, 893-899 (1999).
74. Prestwood KM, Unson C, Kuildorff M, Cushman M: The effect of different dose of micronized 17-β estrachol on C-reactive protein, interleukin 6, and lipid in older women. J. Gerontol. Biol. Sci. Med. Sci. 59, 827-832 (2004).
75. Cushman M, Legault C, Barrett-Connor E et al.: Effects of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 100, 717-722 (1999).
76. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP: Female hormones and thrombosis. Afterioscler. Thromb. Vasc. Biol. 22, 201-210 (2002).
77. Fillit HM: The role of hormone replacement therapy in the pvevention of Alzheimer's disease. Arch. Intern. Med. 162, 1934-1942 (2002).
78. Genazzani AR, Gambacciani M: Hormone replacement therapy: the perspective for the 21st Century. Maturitas 32, 11-17 (1999).
79. Wenger NK, Speroff L, Packard B: Cardiovascular Health and Disease in Women. N. Engl. J. Med. 329, 247-256 (1993).
80. Leys D: Ischemic strokes in young adults. Rev. Med. Intern. 24(9), 585-593 (2003).
81. Littleton-Kearney MT, Klaus JA, Hurn PD: Effects of combined oral conjugated estrogens and medroxyprogesterone acetate on brain infarction size after experimental stroke in rat. J. Cereb. Blood Flow Metab. 25(4), 421-426 (2005).
82. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: Estrogen replacement after ischemic stroke: report of the Women's Estrogen for Stroke Trial (WEST). N. Engl. J. Med. 345, 1243-1249 (2001).
83. Falkeborn M, Persson I, Terènt A, Adami H-O, Lithell H, Bergström R: Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch. Intern. Med. 153, 1201-1209 (1993).
84. Wassertheil-Smoller S, Hendrix SL, Limacher M et al.: Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 289, 2673-2684 (2003).
85. Gray LJ, Bath PMW: The effect of hormone replacement therapy on stroke risk, type and outcome: a systematic review of data from randomised controlled trials. Cerebrovasc. Dis. 17(Suppl. 5), 18 (2004).
86. Grady D, Rubin SM, Petitti DB et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117, 1016-1037 (1992).
87. Grodstein F, Stampfer M: The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog. Cardiovasc. Dis. 38, 199-210 (1995).
88. Upmark E: Life and death without ovaries. Acta Med. Scand. 172, 129-135 (1962).
89. Wilson PWF, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N. Engl. J. Med. 313, 1038-1043 (1985).
90. Byrd BF Jr, Burch JC, Vaughn WK: The effects of long-term estrogen support after hysterectomy. A report of 1016 cases. Ann. Surg. 185, 574-580 (1977).
91. MacMahon B: Cardiovascular disease and non-contraceptive oestrogen therapy. In: Coronary Heart Disease in Young Women. Oliver MF (Ed.). Churchill Livinstone, NY, USA 197-207 (1978).
92. Hunt K, Vessey M, McPherson K: Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br. J. Obstet Gynaecol. 97, 1080-1086 (1990).
93. Schairer C, Adarni H-O, Hoover R, Persson I: Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 859, 6566-6569 (1997).
94. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133, 933-941 (2000).
95. Li C, Engström G, Hedblad B, Berglund G, Janzon L: Risk of stroke and hormone replacement therapy. a prospective cohort study. Maturitas 54, 11-18 (2006).
96. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279, 688-695 (1998).
97. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD: Postmenopausal hormone replacement: scientific review. JAMA 288, 872-881 (2002).
98. Kawas C, Resnick S, Morrison A et al.: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 48, 1517-1521 (1997).
99. Tang M-X, Jacobs D, Stern Y et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348, 429-432 (1996).
100. Zandi PP, Carlson MC, Plassman BL et al.: Hormone replacement therapy and incidence of Alzheimer's disease in older women: the Cache County Study: JAMA 288, 2123-2129 (2002).
101. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J: The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. Neuroscience 101, 485-512 (2000).
102. Low LF, Anstey KJ: Hormone replacement therapy and cognitive performance in postmenopausal women - a review by cognitive domain. Neurosci. Biobehav. Rev. 30(1), 66-84 (2006).
103. Shumaker S, Legault C, Kuller L et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004).
104. Simon JA, Hsia J, Cauley JA et al.: Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 103, 638-642 (2001).
105. Viscoh CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am. J. Obstet. Gynecol. 192(2), 387-393 (2005).
106. Mosca L, Banka CL, Benjamin EJ et al.; for the Expert Panel/ Writing Group: Evidence-based guidelines for cardiovascular disease prevention in women. J. Am. Coll Cardiol. 49(11), 1230-1250 (2007).
107. LeBlanc ES, Janowsky J, Chan BK, Nelson HD: Hormone replacement therapy and cognition: systemic review and meta-analysis. JAMA 285, 1489-1499 (2001).
108. Grady D, Yaffe K, Kristof M, Lin E Richards C, Barrett-Connor E: Effect of postmenopausal hormone therapy on cognition function: the Heart and Estrogen/Progestin Replacement Study. Am. J. Med. 113, 543-548 (2002).
109. Espeland MA, Rapp SR, Shumaker SA et al.; WHIMS Investigators: Conjugated equine estrogens and global cognitive function in postmenopausal women: Wome's Health Initiative Memory Study. JAMA 291, 2959-2968 (2004).
110. Petersen RC, Doody R, Kurz A et al.: Current concepts in mild cognitive impairment. Arich. Neurol. 58, 1985-1992 (2001).
111. Hogervorst E, Yaffe K, Richards M, Hupper F: Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst. Rev. CD003122 (2002).
112. Klein KP: Women's cognitive health: postmenopausal dementia and the Women's Health Initiative Memory Study. Womens Health Issues 143(3), 71-74 (2004).
113. Iadecola C, Gorelick PB: Converging pathogenic mechanism in vascular and neurodegenerative dementia. Stroke 34, 335-337 (2003).
114. Vickers MR, Martin J, Meade TW; WISDOM study team: The Women's International Study of Long-Duration Oestrogen after Menopause (WISDOM): a randomized controlled trial. BMC Womens Health 7, 2(2 007).
115. Vickers MR, MacLennan AH, Lawton B et al.; for the WISDOM team: Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Br. Med. J. 335, 239 (2007).
116. Harmon S, Brinton E, Cedars M et al.: KEEPS: the Kronos Early Estrogen Prevention Study. Climateric 8, 3-12 (2005).